Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report) shares traded down 13.9% on Wednesday. The company traded as low as $1.14 and last traded at $1.14. Approximately 500 shares traded hands during trading, a decline of 99% from the average session volume of 54,453 shares. The stock had previously closed at $1.3240.
Mesoblast Price Performance
The firm has a 50-day moving average of $1.60 and a 200-day moving average of $1.63.
About Mesoblast
Mesoblast Limited is an Australia-based biotechnology company that develops allogeneic cellular medicines designed to treat serious inflammatory and immune-mediated conditions. Its technology is based primarily on mesenchymal lineage cells, which are intended to regulate immune responses, reduce inflammation and support tissue repair without requiring cells to be collected from the individual patient.
The company’s lead product, remestemcel-L, is marketed in the United States under the brand name Ryoncil for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.
Further Reading
- Five stocks we like better than Mesoblast
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
